Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D
摘要:
The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.
[EN] 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER<br/>[FR] COMPOSÉS DE 2,4'-BIPYRIDINYLE COMME INHIBITEURS DE LA PROTÉINE KINASE D UTILES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE ET DU CANCER
申请人:NOVARTIS AG
公开号:WO2009150230A1
公开(公告)日:2009-12-17
The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
本发明提供了式I的新型有机化合物:其使用方法和药物组合物。
2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER
申请人:Novartis AG
公开号:EP2310381A1
公开(公告)日:2011-04-20
Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D
作者:Erik L. Meredith、Kimberly Beattie、Robin Burgis、Michael Capparelli、Joseph Chapo、Lucian DiPietro、Gabriel Gamber、Istvan Enyedy、David B. Hood、Vinayak Hosagrahara、Charles Jewell、Keith A. Koch、Wendy Lee、Douglas D. Lemon、Timothy A. McKinsey、Karl Miranda、Nikos Pagratis、Dillon Phan、Craig Plato、Chang Rao、Olga Rozhitskaya、Nicolas Soldermann、Clayton Springer、Maurice van Eis、Richard B. Vega、Wanlin Yan、Qingming Zhu、Lauren G. Monovich
DOI:10.1021/jm100076w
日期:2010.8.12
The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.
ORGANIC COMPOUNDS
申请人:Burgis Robin
公开号:US20110092505A1
公开(公告)日:2011-04-21
The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.